Analysis of Antibody Neutralization Efficiency and Cellular Immunity in SARS-CoV-2-Positive Individuals Identified in At-Risk Individuals [Added supplements: COVID-19 Variant Supplement, COVID-19 Variant Network]

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:8 publications

Grant number: 172722, 175515, 175569

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $2,050,500
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Marc-Andre Langlois
  • Research Location

    Canada
  • Lead Research Institution

    University of Ottawa Biochemistry, Microbiology & Immunology
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)Older adults (65 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Hospital personnel

Abstract

As the COVID-19 pandemic continues its deadly course around the globe, research efforts are closely focused on viral immunity, antibody responses, and vaccine development. Increasing data from multiple reputable international medical sources now indicate that exposure to the COVID-19 virus induces an antibody response in nearly all exposed individuals. However, questions remain about the protective value of these antibodies against repeat exposure to the virus and how long this protection will last. Furthermore, it is unclear whether there are differences in the virus-neutralizing ability of antibodies produced by asymptomatic carriers of the virus and individuals that develop severe COVID-19 infection. Answers to these important questions will enable us to predict the likelihood of additional waves of COVID-19 as well as inform public health efforts and vaccine development. For our study we will recruit a total of 1,000 healthy primary school teachers, daycare personnel, frontline medical workers in hospitals, and elderly people living in retirement homes. We will monitor them every two weeks for the virus and monthly for antibodies. We will regularly report back the data to the participants. The information learned from our laboratory will have five major outcomes: 1) It will enable early detection of infection and thereby greatly reduced the spread of the virus; 2) We will acquire a better sense of the numbers of asymptomatic and symptomatic individuals exposed to COVID-19; 3) Antibodies in the blood of those infected will be tested to see how well it can neutralize the virus; 4) Critical information about immunity to COVID-19 and how long the immunity will last will be shared with the scientific community and local/regional/national health authorities; and 5) This new knowledge will help vaccine developers make the right decisions about how to create their vaccines and how to give them to all of us.

Publicationslinked via Europe PMC

The Heterogeneous Diffusion of Polystyrene Nanoparticles and the Effect on the Expression of Quorum-Sensing Genes and EPS Production as a Function of Particle Charge and Biofilm Age.

Ex vivo microRNA and gene expression profiling of human Tr1-like cells suggests a role for miR-92a and -125a in the regulation of EOMES and IL-10R.

An optimized workflow for CRISPR-Cas9 deletion of surface and intracellular factors in primary human T lymphocytes.

Vitamin D and IFN-β Modulate the Inflammatory Gene Expression Program of Primary Human T Lymphocytes.

A molecular network regulating the proinflammatory phenotype of human memory T lymphocytes.

DNA (Hydroxy)Methylation in T Helper Lymphocytes.

The contribution of active and passive mechanisms of 5mC and 5hmC removal in human T lymphocytes is differentiation- and activation-dependent.

MicroRNAs as modulators of T cell functions in cancer.